PACS Stock Analysis: PACS | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 7.040m USD | 12M Return: 237.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 37.8M
Qual. Beats: 1
Rev. Trend: 100.0%
Warnings
Tailwinds
Seasonality 2.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
PACS Group, Inc. is a U.S. operator of skilled nursing facilities (SNFs) and assisted living facilities (ALFs), with additional senior care and independent living offerings. The company also acquires, owns, and leases healthcare-related real estate, a common capital strategy in the post-acute care sector that allows operators to monetize property while maintaining operational control through lease agreements.
Founded in 2013 and headquartered in Salt Lake City, Utah, PACS went public on the NYSE on April 11, 2024. It is classified within the Health Care Facilities sub-industry, a segment that serves primarily elderly and post-acute patients requiring varying levels of clinical and daily-living support.
- Medicare reimbursement rate changes impact skilled nursing revenue
- Staffing wage inflation pressures operating margins
- Aggressive acquisition strategy expands facility footprint
| Net Income: 243.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.85 > 1.0 |
| NWC/Revenue: -0.10% < 20% (prev -0.58%; Δ 0.48% < -1%) |
| CFO/TA 0.09 > 3% & CFO 490.3m > Net Income 243.8m |
| Net Debt (6.33b) to EBITDA (442.5m): 14.31 < 3 |
| Current Ratio: 0.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (162.1m) vs 12m ago 4.45% < -2% |
| Gross Margin: 17.46% > 18% (prev 13.18%; Δ 4.28% > 0.5%) |
| Asset Turnover: 97.37% > 50% (prev 81.78%; Δ 15.59% > 0%) |
| Interest Coverage Ratio: 13.68 > 6 (EBIT TTM 381.5m / Interest Expense TTM 27.9m) |
| A: -0.00 (Total Current Assets 1.07b - Total Current Liabilities 1.07b) / Total Assets 5.66b |
| B: 0.07 (Retained Earnings 390.3m / Total Assets 5.66b) |
| C: 0.07 (EBIT TTM 381.5m / Avg Total Assets 5.58b) |
| D: 0.22 (Book Value of Equity 1.04b / Total Liabilities 4.62b) |
| Altman-Z'' = 0.91 = BB |
| DSRI: 0.89 (Receivables 733.2m/680.7m, Revenue 5.43b/4.49b) |
| GMI: 0.75 (GM 13.18% / 17.46%) |
| AQI: 1.09 (AQ_t 0.07 / AQ_t-1 0.06) |
| SGI: 1.21 (Revenue 5.43b / 4.49b) |
| TATA: -0.04 (NI 243.8m - CFO 490.3m) / TA 5.66b) |
| Beneish M = -3.14 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 43.22 with a total of 687,963 shares traded. Over the past week, the price has changed by -2.83%, over one month by +25.90%, over three months by +28.06% and over the past year by +237.92%.
Current recommended Stop Loss: 40.80 (which is 5.6% or 1.2 ATR below the current price).
PACS has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy PACS.
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 49.7 | 14.9% |
P/E Trailing = 28.6968
P/E Forward = 19.5695
P/S = 1.2959
P/B = 6.7632
P/EG = 1.3045
Revenue TTM = 5.43b USD
EBIT TTM = 381.5m USD
EBITDA TTM = 442.5m USD
Long Term Debt = 284.8m USD (from longTermDebt, last quarter)
Short Term Debt = 192.3m USD (from shortTermDebt, last quarter)
Debt = 6.58b USD (from shortLongTermDebtTotal, last quarter) + Leases 3.07b
Net Debt = 6.33b USD (calculated: Debt 6.58b - CCE 248.0m)
Enterprise Value = 13.4b USD (7.04b + Debt 6.58b - CCE 248.0m)
Interest Coverage Ratio = 13.68 (Ebit TTM 381.5m / Interest Expense TTM 27.9m)
EV/FCF = 56.41x (Enterprise Value 13.4b / FCF TTM 237.0m)
FCF Yield = 1.77% (FCF TTM 237.0m / Enterprise Value 13.4b)
FCF Margin = 4.36% (FCF TTM 237.0m / Revenue TTM 5.43b)
Net Margin = 4.49% (Net Income TTM 243.8m / Revenue TTM 5.43b)
Gross Margin = 17.46% ((Revenue TTM 5.43b - Cost of Revenue TTM 4.48b) / Revenue TTM)
Gross Margin QoQ = 16.36% (prev 16.46%)
Tobins Q-Ratio = 2.36 (Enterprise Value 13.4b / Total Assets 5.66b)
Interest Expense / Debt = 0.42% (Interest Expense 27.9m / Debt 6.58b)
Taxrate = 31.43% (111.7m / 355.5m)
NOPAT = 261.6m (EBIT 381.5m * (1 - 31.43%))
Current Ratio = 0.99 (Total Current Assets 1.07b / Total Current Liabilities 1.07b)
Debt / Equity = 6.34 (Debt 6.58b / totalStockholderEquity, last quarter 1.04b)
Debt / EBITDA = 14.31 (Net Debt 6.33b / EBITDA 442.5m)
Debt / FCF = 26.71 (Net Debt 6.33b / FCF TTM 237.0m)
Total Stockholder Equity = 915.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.37% (Net Income 243.8m / Total Assets 5.66b)
RoE = 26.63% (Net Income TTM 243.8m / Total Stockholder Equity 915.5m)
RoCE = 31.78% (EBIT 381.5m / Capital Employed (Equity 915.5m + L.T.Debt 284.8m))
RoIC = 5.77% (NOPAT 261.6m / Invested Capital 4.53b)
WACC = 5.43% (E(7.04b)/V(13.6b) * Re(10.23%) + D(6.58b)/V(13.6b) * Rd(0.42%) * (1-Tc(0.31)))
Discount Rate = 10.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 78.21 | Cagr: 3.11%
[DCF] Terminal Value 73.22% ; FCFF base≈252.9m ; Y1≈223.2m ; Y5≈182.7m
[DCF] Fair Price = N/A (negative equity: EV 2.93b - Net Debt 6.33b = -3.40b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: 99.98 | Revenue CAGR: 30.38% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.56 | Chg30d=-2.35% | Revisions=+40% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.56 | Chg30d=-1.66% | Revisions=-17% | Analysts=4
EPS current Year (2026-12-31): EPS=2.37 | Chg30d=-0.92% | Revisions=+57% | GrowthEPS=+30.8% | GrowthRev=+8.4%
EPS next Year (2027-12-31): EPS=2.51 | Chg30d=-0.92% | Revisions=+29% | GrowthEPS=+6.1% | GrowthRev=+6.6%
[Analyst] Revisions Ratio: +44% (up=10, down=3)